Testosterone Undecanoate: The 12-Week TRT Option (Aveed/Nebido) Explained

Most TRT patients inject testosterone cypionate or enanthate once or twice a week. Testosterone undecanoate operates on a completely different schedule: after two loading doses spaced four weeks apart, maintenance injections come every 10 to 14 weeks. That is roughly one clinic visit per quarter instead of 26 to 52 self-injections per year.

The trade-off is that undecanoate is almost never available through at-home telehealth programs. In the United States, the FDA-approved brand (Aveed) carries a Risk Evaluation and Mitigation Strategy, or REMS, that restricts distribution to certified healthcare settings. Patients receive the injection in-clinic and must be observed for 30 minutes afterward due to a rare risk of post-injection pulmonary oil microembolism. This makes undecanoate the opposite of the convenience-first model that most online TRT clinics sell.

What Is Testosterone Undecanoate?

Testosterone undecanoate is a long-acting testosterone ester dissolved in castor oil. The molecule's chemical structure — an 11-carbon undecanoic acid chain attached to the 17-beta hydroxyl position — makes it significantly more lipophilic than the 7-carbon enanthate or 8-carbon cypionate esters. That extra lipophilicity slows its release from the intramuscular depot, extending the elimination half-life to approximately 36 days in humans.

Nebido (the European and Australian brand by Bayer) has been available since the early 2000s and is the most widely used testosterone formulation worldwide. In the United States, Aveed received FDA approval in March 2014 for men with confirmed hypogonadism due to conditions affecting the testicles, pituitary gland, or hypothalamus. Each milliliter contains 250 mg of testosterone undecanoate, and the standard maintenance dose is 750 mg (3 mL) administered as a deep slow intramuscular gluteal injection.

Dosing Schedule: Loading, Maintenance, and Timing

The undecanoate protocol has three phases. The first injection is a 750 mg loading dose. Four weeks later, a second 750 mg injection. Thereafter, maintenance injections are given every 10 to 14 weeks based on trough testosterone levels. The interval is not fixed — clinicians measure the patient's total testosterone immediately before the scheduled injection and adjust the timing if levels have drifted below the target range.

This is fundamentally different from weekly cypionate dosing, where patients typically set their dose and injection frequency and make fine adjustments based on mid-cycle blood work. Undecanoate requires less frequent dosing but demands more careful interval management. If you wait too long between maintenance injections, testosterone levels drop below therapeutic range and symptoms return. Inject too early, and levels may climb supraphysiologic.

Stability and Trough Levels

The primary clinical advantage of undecanoate is hormonal stability. A 2012 study by Zitzmann and colleagues in the Journal of Clinical Endocrinology & Metabolism (n = 227 men followed for up to 42 months) found that trough total testosterone averaged 418 ng/dL at steady state, with most patients (84%) maintaining levels between 280 and 880 ng/dL across the full dosing interval. Fluctuations were considerably flatter than what is typically seen with weekly enanthate or cypionate injections.

By contrast, weekly testosterone cypionate at 100-150 mg produces a peak-to-trough swing of roughly 150-250 ng/dL between days 1-3 and days 6-7 after injection. Many patients on weekly protocols report this as a noticeable difference in energy, mood, and well-being. Undecanoate patients generally do not report these weekly oscillations because the 36-day half-life creates a much gentler curve.

The TRAVERSE trial (2023) and subsequent 2025 FDA label change removing the black box warning from testosterone products included men on various testosterone formulations, though gel formulations predominated. The cardiovascular safety finding — no excess risk versus placebo — applies to testosterone replacement generally, not to any single formulation or ester.

Availability and Access in the United States

Here is where undecanoate gets complicated for American patients. Aveed is FDA-approved but carries a REMS restriction. Only certified healthcare facilities can stock and administer it. Patients cannot purchase it from a pharmacy for self-injection at home. This means you must find a urologist, endocrinologist, or TRT clinic that both holds the certification and is willing to administer the injections on schedule.

Most online TRT clinics — including Defy Medical, Marek Health, Fountain TRT, and others — do not currently offer testosterone undecanoate. They prescribe cypionate and enanthate, which patients self-administer subcutaneously or intramuscularly at home. The business model of telehealth TRT depends on home-based treatment; the REMS requirement for undecanoate is incompatible with it.

In Europe, Nebido is widely available through urology and endocrinology practices without the REMS restrictions, and patients report easier access. The formulation is also available in Canada (Androne) and Australia (Reandron).

Side Effects and Safety Considerations

The side effect profile of testosterone undecanoate mirrors that of other injectable testosterone esters: potential for elevated hematocrit requiring therapeutic phlebotomy, acne, fluid retention, suppressed spermatogenesis, and estradiol-related effects such as gynecomastia in susceptible individuals. The slower release does not eliminate these risks — it only changes the temporal pattern in which they may emerge.

The unique safety consideration with undecanoate is the risk of post-injection pulmonary oil microembolism (POME). This occurs when a small amount of the castor oil vehicle enters the bloodstream during injection, travels to the lungs, and causes transient symptoms: coughing, shortness of breath, chest tightness, and dizziness. The REMS protocol requires a 30-minute post-injection observation period specifically to monitor for this event. In clinical trials of over 2,400 injections, POME occurred in approximately 0.2-0.3% of cases and resolved without intervention. No cases were life-threatening.

As with all testosterone formulations, monitoring is essential. The Endocrine Society guidelines recommend checking hematocrit, total testosterone (trough), PSA (in men over 40), and lipid panels at baseline, 3-6 months after starting therapy, and annually thereafter. With undecanoate, trough levels should be drawn immediately before each scheduled injection to determine if the interval needs adjustment.

Who Is Undecanoate Best Suited For?

Testosterone undecanoate makes sense for men who meet several criteria: confirmed hypogonadism with testosterone below 300 ng/dL on at least two morning labs; desire for infrequent dosing; access to a certified clinic willing to administer the injections; and no contraindications to injectable testosterone (such as active prostate cancer, severe untreated sleep apnea, or elevated hematocrit at baseline).

It is particularly well-suited for men who have struggled with compliance on weekly protocols — either forgetting injections, experiencing significant peak-to-trrough symptom swings, or traveling frequently and needing a stable schedule. The quarterly injection model eliminates the weekly burden while maintaining therapeutic levels.

It is less suitable for men who want complete control over their dosing schedule, those in regions with no certified prescribing facilities, or patients who may need rapid dose adjustments during the optimization phase. In the first 3-6 months of TRT, some clinicians prefer shorter-acting esters because they allow quicker fine-tuning in response to blood work and symptom feedback.

Cost Considerations

Aveed pricing in the United States varies significantly by provider and insurance coverage. Because it must be administered in a clinical setting, costs include both the medication (750 mg per maintenance injection, three to four times per year) and the facility/administration fee per visit. Some insurance plans cover Aveed when diagnostic criteria for hypogonadism are documented; Medicare coverage depends on specific criteria and regional policies. Without insurance, the per-injection cost can range from several hundred to over a thousand dollars including the clinical visit.

Compared to monthly costs of self-injected cypionate (typically $10-40 per month for the medication through compounding pharmacies or retail sources), undecanoate's per-visit cost is higher, but the frequency of visits is much lower. Total annual cost depends heavily on insurance coverage and local clinic fees.

Key Takeaways

• Quarterly dosing: Testosterone undecanoate requires only 3-5 injections per year after a two-dose loading phase, compared to 26-52 self-injections with weekly protocols.
• Smoother levels: The 36-day half-life produces flatter testosterone curves with minimal peak-to-trough fluctuation, reducing the weekly energy crashes some patients experience on cypionate or enanthate.
• REMS restricted: In the U.S., Aveed can only be administered in certified healthcare facilities with 30-minute post-injection observation. Most online TRT clinics do not offer it.
• Monitoring required: Trough testosterone should be checked before each scheduled injection to determine if the 10-14 week interval needs adjustment. Hematocrit, PSA, and lipid monitoring follow standard TRT protocols.
• Not for rapid titration: The long half-life makes undecanoate a poor choice during initial dose optimization. Clinicians often prefer shorter-acting esters for the first 3-6 months.

This article is for informational purposes only and does not constitute medical advice. Testosterone replacement therapy should be initiated and monitored by a qualified healthcare provider. Discuss your specific health profile, medication options, and monitoring requirements with your physician before starting or changing any hormone therapy.